Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 4
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Perrone T, Re F, Galimberti S, Gini G, Capponi M, Vitolo U, Usai SV, Stefani PM, Ballerini F, Liberati AM, Pennese E, Pastore D, Skrypets T, Catellani H, Marcheselli L, Federico M, Luminari S. Nizzoli ME, et al. Among authors: federico m. Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28. Hematol Oncol. 2023. PMID: 37246287 Clinical Trial.
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Massaro F, Stepanishyna Y, Manni M, Luminari S, Galimberti S, Marcheselli L, Visco C, Tecchio C, Stelitano C, Angrilli F, Petrini M, Merli F, Federico M. Massaro F, et al. Among authors: federico m. Br J Haematol. 2021 Mar;192(6):1011-1014. doi: 10.1111/bjh.16714. Epub 2020 May 14. Br J Haematol. 2021. PMID: 32410259 Free article. Clinical Trial.
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
Civallero M, Schroers-Martin JG, Horwitz S, Manni M, Stepanishyna Y, Cabrera ME, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattone C, Skrypets T, Perez Saenz MA, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R. Civallero M, et al. Among authors: federico m. Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19433. Online ahead of print. Br J Haematol. 2024. PMID: 38532575
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.
Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NPC, Pileri SA, Montoto S, Horwitz SM, Cabrera ME, De Souza CA, Nagler A, Luminari S, Ferreri AJM, Carson KR, Re A, Rigacci L, Nassi L, Stepanishyna Y, Federico M, Inghirami G. Chiattone C, et al. Among authors: federico m. Hematol Oncol. 2022 Dec;40(5):953-961. doi: 10.1002/hon.3074. Epub 2022 Sep 15. Hematol Oncol. 2022. PMID: 36083035
Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
Stepanishyna Y, Manni M, Civallero M, Shokun N, Skrypets T, Burtna A, Shapovalenko N, Tytorenko I, Aleksyk O, Pastushenko Y, Gubareva H, Moiseienko K, Kadnikova T, Rudyuk T, Filonenko K, Martynchyk A, Novosad O, Galli GR, Kryachok I, Federico M. Stepanishyna Y, et al. Among authors: federico m. Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352. Online ahead of print. Br J Haematol. 2024. PMID: 38400556
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.
Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Foss FM, et al. Among authors: federico m. Am J Hematol. 2020 Feb;95(2):151-155. doi: 10.1002/ajh.25674. Epub 2019 Nov 25. Am J Hematol. 2020. PMID: 31709579 Free PMC article. Clinical Trial.
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B; Aristotle Consortium. Federico M, et al. Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4. Lancet Haematol. 2018. PMID: 30078408
These findings support the need to inform patients using rituximab nowadays that the risk of transformation is lower than it was before the introduction of rituxumab. FUNDING: Associazione Angela Serra per la Ricerca sul Cancro, European Lymphoma Institute, European Hemato …
These findings support the need to inform patients using rituximab nowadays that the risk of transformation is lower than it was before the …
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattone CS, Horwitz SM, Dlouhy I, Spina M, Hitz F, Montoto S, Nagler A, Martinez V, De Souza CA, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Kim WS. Fox CP, et al. Among authors: federico m. Lancet Haematol. 2020 Apr;7(4):e284-e294. doi: 10.1016/S2352-3026(19)30283-2. Epub 2020 Feb 24. Lancet Haematol. 2020. PMID: 32105608
FUNDING: The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italiana Linfomi, Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, and the National Cancer Institute …
FUNDING: The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italian …